Investor Toolbox
Listen to Call
Recording not yet available.
Read Transcript
Transcript not yet available.
View Infographic
Infographic not yet available.
REGN Coverage
Event
Regeneron Pharmaceuticals Inc (REGN) Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
Feb 26, 2026
Event
Regeneron Pharmaceuticals Inc (REGN) Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
Feb 24, 2026
Event
Regeneron Pharmaceuticals Inc (REGN) Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Feb 19, 2026
Transcript
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Transcript
Feb 2, 2026
Transcript
Regeneron Pharmaceuticals Inc (REGN) Q2 2025 Earnings Call Transcript
Jan 22, 2026
Transcript
Regeneron Pharmaceuticals Inc (REGN) Q3 2025 Earnings Call Transcript
Jan 22, 2026
News
Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls; revenue up 7%
May 4, 2023
Press Release
Earnings: Regeneron Pharmaceuticals (REGN) Q4 profit falls as revenues drop 31%
Feb 3, 2023